Trial Search Results

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFL or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients with NAFL or NASH within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Target PharmaSolutions, Inc.

Stanford Investigator(s):


Inclusion Criteria:

1. Adults and children (age 2 or older) being managed or treated for nonalcoholic fatty
liver disease. Diagnosis is based on the clinical judgement of the care provider.

Exclusion Criteria:

   1. Inability to provide written informed assent/consent

   2. Simultaneous enrollment in another registry, study, or clinical trial where NASH
   treatment outcomes are reported, except where approved or conducted as an adjunct
   project of TARGET-NASH. If a participant elects to enroll in an interventional
   clinical trial during their enrollment in TARGET-NASH, records submissions for the
   participant will be put 'on hold' for the trial duration. When participation in the
   trial is complete, records submissions for TARGET-NASH will resume.

Ages Eligible for Study

2 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Tanvi Chitre